IP Library Granted Patent US 8,546,610
Granted Patent B2
US 8,546,610 · App. 13/218,946 · Granted Oct 1, 2013

Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives

Inventors: Noriyasu Kataoka (Kawasaki, JP); Kotaro Okado (Kawasaki, JP); Tatsuhiro Yamada (Kawasaki, JP); Koichi Fujita (Kawasaki, JP); Tamotsu Suzuki (Kawasaki, JP); Tatsuya Okuzumi (Kawasaki, JP); Masayuki Sugiki (Kawasaki, JP); Akinori Tatara (Kawasaki, JP)
Assignee: Ajinomoto Co., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,610
App. No.
13/218,946
Granted
Oct 1, 2013
Kind
B2
Abstract

A method for preparing a phenylalanine derivative having a quinazoline-dione ring represented by the following formula (1) or a pharmaceutically acceptable salt thereof, comprising the following steps (a), (b) and (c): (a) reacting an acyl phenylalanine derivative represented by the following formula (2): with a carbonyl group-introducing reagent and a specific anthranilic acid derivative to thus form the corresponding carboxy-asymmetric urea derivative; (b) converting the carboxy-asymmetric urea derivative into the corresponding quinazoline-dione derivative in the presence of a carboxyl group-activating agent: (c) if desired, substituting an N-alkyl group for the hydrogen atom bonded to the nitrogen atom present in the quinazoline-dione ring of the quinazoline-dione derivative using an N-alkylation agent and then deprotecting the resulting product, when the substituent R3′ which is a group corresponding to R3 is protected. According to this method, there can be obtained a phenylalanine derivative having a quinazoline-dione skeleton in a industrially favorably high yield.

Claims (3)

1. A compound represented by the following formula (3-1) or a pharmaceutically acceptable salt thereof:

wherein R3″ represents a member selected from the group consisting of N-alkyl-N-formyl-aminoalkyl groups, N-alkyl-N-alkylcarbonyl-aminoalkyl groups, and N-alkyl-N-alkoxycarbonyl-aminoalkyl groups.

2. A compound represented by the following formulas or pharmaceutically acceptable salt thereof:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
Priority Claims (1)
JP 2006-315837 · Nov 22, 2006 · national
Continuity (3)
Division 12470846 · May 22, 2009
Continuation PCTJP2007072615 · Nov 22, 2007
Related Publication 20110313154A1 · Dec 22, 2011